Gilead Sciences Gets Europe Marketing Authorization for Vemlidy

Gilead Sciences shares gained 1% in early pre-market trade Wednesday after the biopharmaceutical firm said the European Commission granted it marketing authorization for Vemlidy 25mg, a once-daily tablet for the treatment of chronic hepatitis B virus infection in adults and adolescents.

Vemlidy was approved by the U.S. Food and Drug Administration on Nov. 10 for the treatment of chronic HBV infection in adults with compensated liver disease, and by the Japanese Ministry of Health, Labour and Welfare on Dec. 19 for the suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function.

Leave a Comment